Quantitative real-time-PCR (qRT-PCR) and Western-Blot were used to detect the expression of intestinal markers: Caudal-related homeobox

2 (CDX2), sucrose-isomaltase (SI), mucin 2 (MUC2) GS-1101 in vitro and Kruppel-like factor 4 (Klf4). MiRNA microarray was employed to profile miRNA expression of GES-1 cells before and after bile acids stimulation. Functional studies were carried out by transfecting GES-1 cells with miRNA mimics or inhibitor. Results: The mRNA and protein levels of CDX2, SI, MUC2 and Klf4 were increased in bile acids induced GES-1 cell, which exhibited dose and time dependent manners. MiRNA microarray data showed that bile acids-stimulated cells exhibited a different miRNA profile from the unstimulated control, which was confirmed by qRT-PCR. Among the up-regulated miRNAs, miR-92a showed the highest change. Transfection of GES-1 and gastric cancer BGC-823 cells with miR-92a mimics could increase the mRNA and protein levels of CDX2 and SI, while transfection Cobimetinib with miR-92a inhibitor decreased the CDX2 and SI levels. Conclusion: MiRNAs are involved in bile acids-induced metaplastic changes of gastric

epithelial cells. miR-92a has a potential role in promoting bile acids-induced gastric IM. Key Word(s): 1. IM; 2. CDX2; 3. miR-92a; Presenting Author: ILKKAJUHANI VOHLONEN Additional Authors: Corresponding Author: ILKKAJUHANI VOHLONEN Affiliations: University of Eastern Finland Objective: Background Atrophic gastritis (AG) and acid free stomach are known risk conditions for gastric cancer. In Finland, we investigated whether screening for AG with serum pepsinogen I (SPGI), followed with endoscopic surveillance, had an effect on gastric cancer mortality. Methods: Methods In 1994–1996, 16,872 men aged 51–65 years were invited for screening with SPGI ELISA assay. In the screened cohort of 12,175 men, the SPGI was low (25 microg/l or before less) in 5% of men, indicating a moderate or severe AG in gastric corpus and fundus. A diagnostic gastroscopy was performed on 435 men with low SPGI and premalignant lesions were found in 56 men. The effectiveness of the screening 15 years later was assessed by standardized mortality rate (SMR) and

by potential years of life lost (PYLL) and the rate of PYLL for gastric cancer. Results: Results According to epidemiological data, expected number of deaths due to stomach cancer without screening would have been 51. Mortality from stomach cancer was reduced to half and the PYLL value was reduced to one third compared with the non-screened population. For the screened, the PYLL-value per death due to stomach cancer was 10.9 years while for the non-screened it was 19.9 years. Reduction in SMR due to stomach cancer was evident about 4 to 9 years after screening. When corrections for confounding factors and participation bias were made, efficacy of SPGI screening on the reduction of mortality due to gastric cancer was estimated to be 30% and on the reduction of PYLL 60%.